Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-28T16:02:10.242Z Has data issue: false hasContentIssue false

Gut Hormones in Glucose Homeostasis

Published online by Cambridge University Press:  28 February 2007

V Marks
Affiliation:
School of Biological Sciences, University of Surrey, Guildford GU2 5XH
Linda Morgan
Affiliation:
School of Biological Sciences, University of Surrey, Guildford GU2 5XH
J Oben
Affiliation:
School of Biological Sciences, University of Surrey, Guildford GU2 5XH
R Elliott
Affiliation:
School of Biological Sciences, University of Surrey, Guildford GU2 5XH
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Meeting Report
Copyright
Copyright © The Nutrition Society 1991

References

Andersen, D. K., Elahi, D., Brown, J. C., Tobin, J. D. & Andres, R. (1978). Oral glucose augmentation of insulin secretion. Journal of Clinical Investigation 62, 152161.CrossRefGoogle ScholarPubMed
Arendt, J., Hampton, S., English, J., Kwasowski, P. & Marks, V. (1982). 24-hour profiles of melatonin, cortisol, insulin. C-peptide and GIP following a meal and subsequent fasting. Clinical Endocrinology 16, 8995.CrossRefGoogle ScholarPubMed
Bailey, C. J. & Flatt, P. R. (1988). Thc enteroinsular axis in animals with hyperinsulinaemic and hypoinsulinaemic diabetes. Frontiers in Diabetes Research II . pp. 217224 [Shafrir, E. and Renold, A. E., editors]. London: John Libbey and Co.Google Scholar
Block, M. B., Hofeldt, F. D., Lufkin, E. G., Haglar, L. & Herman, R. H. (1977). The response of glucagon-like immunoreactivity to reactive hypoglycemia. Military Medicine 142, 3237.CrossRefGoogle ScholarPubMed
Bloom, S. R., Royston, C. M. S. & Thomson, J. P. S. (1972). Enteroglucagon release in the dumping syndrome. Lancet ii, 789793.Google Scholar
Brown, J. C. (1982). Gastric Inhibitory Polypeptide. Heidelberg & New York: Springer-Verlag.Google Scholar
Brown, J. C. & Dryburgh, J. R. (1971). A gastric inhibitory polypeptide II: the complete amino acid sequence. Canadian Journal of Biochemistry 49, 867872.CrossRefGoogle ScholarPubMed
Brown, J. C., Mutt, V. & Pederson, R. A. (1970). Further purification of a polypeptide demonstrating enterogastrone activity. Journal of Physiology 209, 5764.CrossRefGoogle ScholarPubMed
Charles, M. A. & Waldeck, N. (1981). Excessive circulating large molecular weight immunoreactive glucagon components in subjects with the idiopathic postprandial syndrome. Journal of Clinicul Endocrinology and Metabolism 53, 366371.Google Scholar
Creutzfeldt, W. (1979). The incretin concept today. Diabetologia 16, 7585.Google Scholar
Creutzfeldt, W. & Ebert, R. (1985). New developments in the incretin concept. Diabetologia 28, 565573.CrossRefGoogle ScholarPubMed
Dupré, J., Ross, S. A., Watson, D. & Brown, J. C. (1973). Stimulation of insulin secretion by gastric inhibitory polypeptide in man. Journal of Clinical Endocrinology and Metabolism 37, 826828.Google Scholar
Ebert, R. & Creutzfeldt, W. (1982). Influence of gastric inhibitory polypeptide antiserum on glucose-stimulated insulin secretion in rats. Endocrinology 111, 16011606.CrossRefGoogle Scholar
Elahi, D., Andersen, D. K., Muller, D. C., Tobin, J. D., Brown, J. C. & Andres, R. (1984). The enteric enhancement of glucose-stimulated insulin release: the role of GIP in aging, obesity and non-insulin dependent diabetes mellitus. Diabetes 33, 950957.Google Scholar
Foster, G. L. (1923). Studies on carbohydrate metabolism: I. Some comparisons of blood sugar concentration in venous blood and finger prick blood. Journal of Biological Chemistry 55, 291302.CrossRefGoogle Scholar
ke, R., Fehmann, H.-C. & Göke, B. (1991). Glucagon-like peptide-1 (7-36) amide is a new incretin/enterogastrone candidate. European Journal of Clinical Investigation 21, 135144.Google Scholar
Hampton, S. M., Morgan, L. M., Tredger, J. A., Cramb, R. & Marks, V. (1986). Insulin and C-peptide levels after oral and intravenous glucose: contribution of enteroinsular axis to insulin secretion. Diabetes 35, 612616.Google Scholar
Holst, J. J., Ørskov, C. & Bersani, M. (1991). Heterogeneity of islet hormones. In The Endocrine Pancreas, pp. 125149 [Samols, E., editor]. New York: Raven Press.Google Scholar
Jones, I. R., Owens, D. K., Luzio, S. D. & Hayes, T. M. (1989 a). Obesity is associated with increased post-prandial GIP levels which are not reduced by dietary restriction and weight loss. Diabète & Métabolisme Paris 15, 1122.Google Scholar
Jones, I. R., Owens, D. R., Luzio, S. & Hayes, T. M. (1989 b). Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in Type 2 (non-insulin-dependent) diabetes mellitus. Hormone Metabolism Researc 21, 2326.Google Scholar
Komatsu, R., Matsuyama, T., Namba, M., Wanatabe, N., Itoh, H., Kono, N. & Tarui, S. (1989). Glucagonostatic acid insulinotropic action of glucagon-like peptide 1 (7-36) amide. Diabetes 38, 902905.CrossRefGoogle Scholar
Kreymann, B., Ghatei, M. A., Williams, G. & Bloom, S. R. (1987). Glucagon-like peptide- 1 (7-36): a physiological incretin in man. Lancet ii, 13001304.Google Scholar
McIntyre, N., Holdsworth, C. D. & Turner, D. S. (1964). New interpretation of oral glucose tolerance. Lancet ii, 2021.Google Scholar
Makman, M. H. & Sutherland, E. W. (1964). Use of liver adenyl cyclase for assay of glucagon in human gastrointestinal tract and panereas. Endocrinology 75, 127134.CrossRefGoogle Scholar
Marks, V. (1970). The effect of fructose and galactose on insulin secretion in man. Proceedings of an International Symposium on the Clinical and Metabolic Aspects of Laevulose, pp. 3741. Crewe: Calmic Ltd.Google Scholar
Marks, V. (1987). Glycaemic stability in healthy subjects: fluctuations in blood glucose concentration during the day. In Hypoglycemia: Serono Symposia Publications no. 38. pp. 1924 [Andreani, D., Marks, V. and Lefebvre, P. J., editors]. New York: Raven Press.Google Scholar
Marks, V. (1988). GIP–the obesity hormone. In Current Approaches: Obesity [James, W. P. T. and Parker, S. W., editors]. London: Duphar Laboratories.Google Scholar
Marks, V. & Morgan, L. (1984). The entero-insular axis. In Recent Advances in Diabetes. pp. 5571. [Nattrass, M. and Santiago, J. V., editors]. Edinburgh: Churchill Livingstone.Google Scholar
Marks, V. & Samols, E. (1970). Intestinal factors in the regulation of insulin secretion. Advances in Metabolic Disorders 4, 138.Google Scholar
Marks, V. & Turner, D. S. (1977). The gastrointestinal hormones with particular reference to their role in the regulation of insulin secretion. Essays in Medical Biochemistry 3, 109152.Google Scholar
Morgan, L. M., Morris, B. A. & Marks, V. (1978). Radioimmunoassay of gastric inhibitory polypeptide. Annals of Clinical Biochemistry 15, 172177.CrossRefGoogle ScholarPubMed
Morgan, L. M., Oben, J., Fletcher, J. & Marks, V. (1991). Metabolic effects of gut peptides. In Control of Lean and Fat Deposition - 51st Easter School in Agricultural Science, Nottingham University (In the Press).Google Scholar
Morgan, L. M., Tredger, J. A. T., Hampton, S. M., French, A. P., Peake, J. C. F. & Marks, V. (1988). The effect of dietary modification and hyperglycaemia in gastric emptying and gastric inhibitory polypeptide (GIP) secretion. British Journal of Nutrition 60, 2937.Google Scholar
Morgan, L. M., Wright, J. W. & Marks, V. (1979). The effect of oral galactose on GIP and insulin secretion in man. Diabetologia 16, 235239.CrossRefGoogle ScholarPubMed
Peters, J. P. & van Slyke, D. D. (1946). Quantitative Clinical Chemistry Interpretations. vol. 1. London: Bailliere, Tindall & Cox.Google Scholar
Samols, E., Tyler, J., Marri, G. & Marks, V. (1965). Stimulation of glucagon secretion by oral glucose. Lancet ii, 12571259.Google Scholar
Samols, E. & Marks, V. (1967). Nouvelles conceptions sur la signification fonctionnelle du glucagon (pancréatique et extrapancréatique). Journees annuelles de Diabétologie de l'Hotel-Dieu, pp. 4346. Paris: Editions Médicales Flammarion.Google Scholar
Samols, E. & Stagner, J. I. (1991). Intraislet and islet-acinar portal systems and their significance. In The Endocrine Pancreas, pp. 93124 [Samols, E., editor]. New York: Raven Press.Google Scholar
Samols, E., Tyler, J., Megyesi, C. & Marks, V. (1966). Immunochemical glucagon in human pancreas, gut and plasma. Lancet ii, 727729.CrossRefGoogle Scholar
Sarson, D. L., Wood, S. M., Holder, D. & Bloom, S. R. (1982). The effect of glucose-dependent insulinotropic polypeptide infused at physiological concentrations on the release of insulin in man. Diabetologia 22, 3336.Google Scholar
Service, F. J. & Nelson, R. L. (1980) Characteristics of glycemic stability. Diabetes Care 3, 5862.Google Scholar
Shuster, L. T., Go, V. L. W., Rizza, R. A., O'Brien, P. C. & Service, F. J. (1988). Potential incretins. Mayo Clinic Proceedings 63, 794800.CrossRefGoogle ScholarPubMed
Sykes, S., Morgan, L. M., English, J. & Marks, V. (1980). Evidence for the preferential stimulation of gastric inhibitory polypeptide secretion in the rat by actively transported carbohydrates and their analogues. Journal of Endocrinology 85, 201207.CrossRefGoogle ScholarPubMed
Takemura, J., Seino, Y., Yamamura, T., Tsuda, K., Seino, S., Itoh, N. & Imura, H. (1982). The role of endogenous gastric inhibitory polypeptide in the enteroinsular axis. Journal of Clinical Endocrinology and Metabolism 54, 909913.Google Scholar
Taminato, T., Seino, Y., Goto, Y., Inoue, Y., Kadowaki, S., Mori, K., Nozawa, M., Yajima, H. & Imura, H. (1977). Synthetic gastric inhibitory polypeptide: stimulatory effect on insulin and glucagon secretion in the rat. Diabetes 26, 480484.Google Scholar
Turner, D. S., Etheridge, L., Marks, V., Brown, J. C. & Mutt, V. (1974). Effectiveness of the intestinal polypeptides. IRP. GIP. VIP and Motilin on insulin release in the rat. Diabetologia 10, 459463.CrossRefGoogle ScholarPubMed
Turner, D. S., Shabaan, A., Etheridge, L. & Marks, V. (1973). The effect of an intestinal polypeptide fraction on insulin release in the rat in vitro and in vivo. Endocrinology 93, 13231328.Google Scholar